Pharmaceutical company Dr Reddy's Laboratories Ltd (BSE:500124) (NSE:DRREDDY) (NYSE:RDY) stated on Friday that it has launched the US Food and Drug Administration (USFDA) approved Deferasirox Tablets for oral suspension in the US market.
According to the company, Deferasirox Tablets for oral suspension are available in 125 mg, 250 mg and 500 mg dosage strengths in bottle count sizes of 30.
Dr Reddy's Deferasirox Tablets for oral suspension are a therapeutically equivalent generic version of Exjade (deferasirox) tablets for oral suspension.
For the most recent 12 months ending in September 2019, the Exjade brand had US sales of about USD113m MAT, according to IQVIA Health. Exjade (deferasirox) tablets for oral suspension are indicated for the treatment of chronically elevated levels of iron in the blood caused by repeated blood transfusions (transfusional hemosiderosis) in patients two years of age and older.
Amneal Names George, Kiely and Yanai to Board of Directors
Civica Rx, Hikma to Ship Heparin and Seven Other Essential Injectable Medicines
US FDA grants approval to Meitheal Pharmaceuticals' Enoxaparin Sodium Injection
BioDuro names Dr Kent Payne as president of Global CMC Solutions
Dr Reddy's Laboratories reports availability of Deferasirox Tablets for oral suspension in US market
Amneal Launches Generic Revatio for Oral Suspension and Generic Amicar Tablets
Dr Reddy's Laboratories unveils Bortezomib for Injection 3.5 mg/vial in the US
Breckenridge wins FDA final approval for Rivastigmine Transdermal System ANDA